BR112018012458A2 - ?composições farmacêuticas que compreendem o derivado da fenilaminopirimidina? - Google Patents

?composições farmacêuticas que compreendem o derivado da fenilaminopirimidina?

Info

Publication number
BR112018012458A2
BR112018012458A2 BR112018012458A BR112018012458A BR112018012458A2 BR 112018012458 A2 BR112018012458 A2 BR 112018012458A2 BR 112018012458 A BR112018012458 A BR 112018012458A BR 112018012458 A BR112018012458 A BR 112018012458A BR 112018012458 A2 BR112018012458 A2 BR 112018012458A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
compositions
phenylaminopyrimidine derivative
nrc
polymorphs
Prior art date
Application number
BR112018012458A
Other languages
English (en)
Inventor
Maheswari Parvataneni Durga
Satya Bhujanga Rao Adibhatla Kali
Mohanty Mitrabhanu
Chowdary Nannapaneni Venkaiah
Satyanarayana Appadwedula Venkata
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Publication of BR112018012458A2 publication Critical patent/BR112018012458A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

uma formulação farmacêutica oral contendo uma quantidade eficaz de nrc-an-019 incluindo os seus sais e polimorfos farmaceuticamente aceitáveis, dispersando num sistema polimérico num estado final de subdivisão para aumentar a biodisponibilidade oral. refere-se também a processos para a preparação de tais composições e uso dessas composições para o tratamento de leucemia mielóide crônica e outros tumores, tais como cancro da cabeça e pescoço, cancro da próstata e semelhantes.
BR112018012458A 2015-12-18 2016-01-30 ?composições farmacêuticas que compreendem o derivado da fenilaminopirimidina? BR112018012458A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN6951CH2015 2015-12-18
PCT/IN2016/050035 WO2017103941A1 (en) 2015-12-18 2016-01-30 Pharmaceutical compositions comprising phenylaminopyrimidine derivative

Publications (1)

Publication Number Publication Date
BR112018012458A2 true BR112018012458A2 (pt) 2018-12-18

Family

ID=59055898

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018012458A BR112018012458A2 (pt) 2015-12-18 2016-01-30 ?composições farmacêuticas que compreendem o derivado da fenilaminopirimidina?

Country Status (32)

Country Link
US (1) US10383872B2 (pt)
EP (1) EP3389633B1 (pt)
JP (2) JP6896738B2 (pt)
KR (1) KR20180102584A (pt)
CN (1) CN108495620B (pt)
AU (1) AU2016373574B2 (pt)
BR (1) BR112018012458A2 (pt)
CA (1) CA3008634A1 (pt)
CL (1) CL2018001590A1 (pt)
CO (1) CO2018007112A2 (pt)
CY (1) CY1124580T1 (pt)
DK (1) DK3389633T3 (pt)
EA (1) EA036513B1 (pt)
ES (1) ES2881883T3 (pt)
GB (1) GB2564262A (pt)
GE (1) GEP20207176B (pt)
HK (1) HK1254573A1 (pt)
HR (1) HRP20211590T1 (pt)
HU (1) HUE056269T2 (pt)
IL (1) IL260085B (pt)
LT (1) LT3389633T (pt)
MA (1) MA44079B1 (pt)
MX (1) MX2018007281A (pt)
PH (1) PH12018501292A1 (pt)
PL (1) PL3389633T3 (pt)
PT (1) PT3389633T (pt)
RS (1) RS62422B1 (pt)
SG (1) SG11201805142RA (pt)
SI (1) SI3389633T1 (pt)
UA (1) UA122592C2 (pt)
WO (1) WO2017103941A1 (pt)
ZA (1) ZA201804203B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202246215A (zh) 2015-12-18 2022-12-01 美商亞德利克斯公司 作為非全身ｔｇｒ５促效劑之經取代之４－苯基吡啶化合物
CZ2017821A3 (cs) * 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
EP3793527A1 (en) * 2018-05-14 2021-03-24 Capsugel Belgium NV Solid dosage forms with high active agent loading
JP7368548B2 (ja) * 2021-07-02 2023-10-24 昊運股▲フン▼有限公司 薬学的組成物及びその使用
CN115583634B (zh) * 2022-09-21 2023-06-06 广东工业大学 一种碳氮聚合物材料的制备方法及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002241268A (ja) * 2000-12-11 2002-08-28 Takeda Chem Ind Ltd 水溶解性が改善された医薬組成物
AU2005281299B2 (en) 2004-09-09 2012-03-15 Natco Pharma Limited Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase
US8067422B2 (en) 2008-03-04 2011-11-29 Natco Pharma Limited Crystal form of phenylamino pyrimidine derivatives
WO2012002547A1 (ja) * 2010-07-02 2012-01-05 富士化学工業株式会社 ボセンタン固体分散体
GB2488788B (en) * 2011-03-07 2013-07-10 Natco Pharma Ltd Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
CN102836159B (zh) * 2011-06-24 2014-12-10 南京圣和药业股份有限公司 达沙替尼分散体及其制备方法和其在片剂中的应用
WO2015095659A2 (en) * 2013-12-20 2015-06-25 Phosphorex, Inc. Indirubin solid dispersion composition

Also Published As

Publication number Publication date
US10383872B2 (en) 2019-08-20
HK1254573A1 (zh) 2019-07-19
IL260085B (en) 2021-09-30
PH12018501292A1 (en) 2019-02-04
GEP20207176B (en) 2020-11-10
AU2016373574B2 (en) 2021-10-14
UA122592C2 (uk) 2020-12-10
EA201891443A1 (ru) 2019-01-31
DK3389633T3 (da) 2021-08-30
PT3389633T (pt) 2021-08-05
GB2564262A (en) 2019-01-09
CO2018007112A2 (es) 2018-07-19
SI3389633T1 (sl) 2021-11-30
AU2016373574A1 (en) 2018-07-12
KR20180102584A (ko) 2018-09-17
SG11201805142RA (en) 2018-07-30
RS62422B1 (sr) 2021-10-29
JP2021059551A (ja) 2021-04-15
GEAP201614833A (pt) 2020-06-25
ES2881883T3 (es) 2021-11-30
MA44079B1 (fr) 2021-10-29
HUE056269T2 (hu) 2022-02-28
EP3389633A4 (en) 2019-08-07
GB201811142D0 (en) 2018-08-22
PL3389633T3 (pl) 2021-12-13
MX2018007281A (es) 2018-11-29
ZA201804203B (en) 2020-08-26
JP6896738B2 (ja) 2021-06-30
IL260085A (en) 2018-07-31
LT3389633T (lt) 2021-09-10
CL2018001590A1 (es) 2018-11-30
CN108495620A (zh) 2018-09-04
US20190015412A1 (en) 2019-01-17
CA3008634A1 (en) 2017-06-22
HRP20211590T1 (hr) 2022-01-07
EP3389633B1 (en) 2021-07-14
WO2017103941A1 (en) 2017-06-22
EA036513B1 (ru) 2020-11-18
MA44079A (fr) 2021-04-21
JP2018538325A (ja) 2018-12-27
CN108495620B (zh) 2021-09-03
CY1124580T1 (el) 2022-07-22
EP3389633A1 (en) 2018-10-24

Similar Documents

Publication Publication Date Title
CY1122566T1 (el) Παραγωγο 6,7,8,9-tetpaϋδpo-3h-πυραζολo[4,3-f] ισοκινολινης χρησιμο στη θεραπευτικη αντιμετωπιση του καρκινου
PH12017500367A1 (en) Compounds that inhibit mcl-1 protein
CL2016001629A1 (es) Compuestos tricíclicos como agentes anticancerígenos
BR112018012458A2 (pt) ?composições farmacêuticas que compreendem o derivado da fenilaminopirimidina?
TN2017000511A1 (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them.
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
UY36112A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
TW201613593A (en) Molecules for administration to ROS1 mutant cancer cells
BR112016026291A2 (pt) Derivados do ácido borônico e usos terapêuticos dos mesmos
BR112019024747A2 (pt) formulações de dose fixa
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
BR112012027743A2 (pt) ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas
CL2018001171A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
MX2015012414A (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
BR112016030733A2 (pt) Derivados de indano e indolina e uso dos mesmos como ativadores de guanilato ciclase solúveis
MX2018000419A (es) Derivados de amida sustituida que tienen actividad multimodal contra el dolor.
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
BR112016005317A2 (pt) derivados de quinazolina e seu uso como inibidores de dna metiltransferase
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
UY35359A (es) 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS SUSTITUIDAS Y MÉTODOS DE USO
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
WO2015044961A3 (en) Pharmaceutical composition comprising capecitabine and cyclophosphamide
BR112018009482A2 (pt) composto, método para preparar um composto, e, composição farmacêutica.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2707 DE 22/11/2022.